The evolution of hematopoietic SCT in myelodysplastic syndrome.
about
Infections in myelodysplastic syndromesNCCN Clinical Practice Guidelines in Oncology: myelodysplastic syndromes.Hematopoietic stem cell transplantation for MDS.Reduced-toxicity conditioning with treosulfan and fludarabine in allogeneic hematopoietic stem cell transplantation for myelodysplastic syndromes: final results of an international prospective phase II trial.Effect of magnetic Fe3O4 nanoparticles with 2-methoxyestradiol on the cell-cycle progression and apoptosis of myelodysplastic syndrome cells.Wogonin inhibits the proliferation of myelodysplastic syndrome cells through the induction of cell cycle arrest and apoptosis.Allogeneic hematopoietic cell transplantation for MDS: for whom, when and how?Myelodysplastic syndromes: clinical practice guidelines in oncology.Allogeneic hematopoietic cell transplantation for myelodysplastic syndrome: current status.Minimal residual disease monitoring and preemptive immunotherapy in myelodysplastic syndrome after allogeneic hematopoietic stem cell transplantation.Imported Disease Screening Prior to Chemotherapy and Bone Marrow Transplantation for Oncohematological Malignancies.Allogeneic hematopoietic stem cell transplantation in adults with myelodysplastic syndrome: Experience of the Argentinean Group of Bone Marrow Transplantation (GATMO).Access to allogeneic hematopoietic SCT for patients with MDS or relapsed AML treated according to protocols of the Dutch Childhood Oncology Group.Impending relapse of myelodysplastic syndrome after allogeneic transplant is difficult to diagnose and requires a multi-modal approach.Feasibility of hypomethylating agents followed by allogeneic hematopoietic cell transplantation in patients with myelodysplastic syndrome.The Wilms' tumor gene-1 is a prognostic factor in myelodysplastic syndrome: a meta analysis.
P2860
Q26859275-3EF4C41D-D890-4177-BD5D-8D1482CA5769Q33393647-ED33BC2E-9B3E-466C-A8BF-16F6D5FACCE2Q33767314-F1C91B14-3960-457D-A3F3-8D2B0B8DE79FQ35193735-60337686-6F41-490E-84CF-7E577CBA3EF1Q35213043-A87903D7-D602-427D-ABD0-3447CE2D7D38Q36224965-BAAC03D1-00BF-41ED-94EC-8F686265650CQ36431041-3C0EFD0F-0769-4965-BAB8-DEADEA81253AQ37723847-A63F72B0-482B-42C1-A60A-BCCC410D090AQ37964938-285EDEFB-8777-4D0E-B229-46EBB9DCF40EQ39683026-4E2599BA-88CB-4370-B238-F88B7AFE2019Q40419395-D1975234-29B3-4126-8C9B-13AC6E350DCBQ40766061-3489FCCA-CCB1-4151-A8C1-674157BB43A0Q43856934-9DED26CA-B196-450A-BA8A-873A74E5B483Q47100970-B99EBBF9-674C-4D02-890D-ACE75B458421Q53429887-EAA382DD-C6B1-401A-ADB4-55F82A305ADCQ55025570-6A4288F4-7B98-44F0-A83A-924B5EBC621C
P2860
The evolution of hematopoietic SCT in myelodysplastic syndrome.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 02 March 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
The evolution of hematopoietic SCT in myelodysplastic syndrome.
@en
The evolution of hematopoietic SCT in myelodysplastic syndrome.
@nl
type
label
The evolution of hematopoietic SCT in myelodysplastic syndrome.
@en
The evolution of hematopoietic SCT in myelodysplastic syndrome.
@nl
prefLabel
The evolution of hematopoietic SCT in myelodysplastic syndrome.
@en
The evolution of hematopoietic SCT in myelodysplastic syndrome.
@nl
P2860
P356
P1476
The evolution of hematopoietic SCT in myelodysplastic syndrome.
@en
P2093
T Kindwall-Keller
P2860
P2888
P304
P356
10.1038/BMT.2009.28
P407
P577
2009-03-02T00:00:00Z